21. THU0152 How should the primary endpoint be analysed in rheumatoid arthritis trials which mandate rescue prior to the clinical endpoint? Analysis of three phase 3 trials of tofacitinib. (23rd January 2014) Authors: Fleischmann, R.; Gruben, D.; Krishnaswami, S.; Zwillich, S.H.; Benda, B.; Mebus, C.A.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. THU0153 Improvements in disease activity score by baseline status: Pooled analysis of five phase 3 studies with tofacitinib (CP-690, 550) in patients with active rheumatoid arthritis. (23rd January 2014) Authors: Fleischmann, R.M.; Krishnaswami, S.; Gruben, D.; Zwillich, S.H.; Mebus, C.; Bradley, J.D. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. THU0225 Tofacitinib Monotherapy is Effective in Methotrexate-NaÏVe Patients with Disease Duration Less Than 6 Months: a Post-HOC Analysis of Early Rheumatoid Arthritis Subjects in a Phase 3 Trial. (23rd January 2014) Authors: Huizinga, T. W. J.; Fleischmann, R.; van Vollenhoven, R.; Gruben, D.; Wilkinson, B.; Koncz, T.; Bradley, J.; Zwillich, S. H.; Benda, B. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population. (23rd January 2014) Authors: Keystone, E.; Fleischmann, R.; van Vollenhoven, R.; Kremer, J.; Gruben, D.; Bradley, J.; Riese, R.; Mebus, C.; Wallenstein, G.; Zwillich, S. H.; Benda, B.; Krishnaswami, S. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. THU0258 Oral Start: Effects of the Oral JAK Inhibitor Tofacitinib Monotherapy Versus Methotrexate on Patient-Reported Outcomes in the Phase 3 Oral Start Trial of Active Rheumatoid Arthritis. (23rd January 2014) Authors: Strand, V.; Fleischmann, R.; Alten, R. E.; Koncz, T.; Zwillich, S. H.; Bradley, J. D.; Gruben, D.; Wilkinson, B.; Krishaswami, S.; Wallenstein, G. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. THU0343 Modelling the Costs and Outcomes Associated with Sequence of Treatment with and Without Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis in the US. (9th June 2015) Authors: Claxton, L.; Taylor, M.; Moynagh, D.; Gruben, D.; Wallenstein, G.; Singh, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗